Advanced search
Publication Cover
Expert Review of Vaccines Volume 18, 2019 - Issue 3
Submit an article Journal homepage
1,225
Views
24
CrossRef citations to date
0
Altmetric
Review

Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis

Sandrine I. SamsonSanofi Pasteur, Swiftwater, PA, USACorrespondence[email protected]
View further author information
,
Phillip S. Leventhal4Clinics, Paris, FranceView further author information
,
Camille SalamandSanofi Pasteur, Lyon, FranceView further author information
,
Ya MengSanofi Pasteur, Swiftwater, PA, USAView further author information
,
Bruce T. SeetSanofi Pasteur, Swiftwater, PA, USA;Department of Molecular Genetics, University of Toronto, Medical Science Building, Toronto, ON, CanadaView further author information
,
Victoria LandolfiSanofi Pasteur, Swiftwater, PA, USAView further author information
,
David GreenbergSanofi Pasteur, Swiftwater, PA, USA;Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USAView further author information
&
Rosalind HollingsworthSanofi Pasteur, Swiftwater, PA, USAView further author information
 show all
Pages 295-308 | Received 17 Oct 2018, Accepted 25 Jan 2019, Published online: 13 Feb 2019

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Leilani Sanchez, Osamu Matsuoka, Satoshi Inoue, Takahiro Inoue, Ya Meng, Takahiro Nakama, Kumiko Kato, Aseem Pandey & Lee-Jah Chang. (2020) Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial. Human Vaccines & Immunotherapeutics 16:4, pages 858-866.
Read now

Articles from other publishers (23)

Luca Pestarino, Alexander Domnich, Andrea Orsi, Federico Bianchi, Elisa Cannavino, Pier Claudio Brasesco, Gianluca Russo, Simone Valbonesi, Giacomo Vallini, Matilde Ogliastro & Giancarlo Icardi. (2023) Rollout of the 2022/2023 Seasonal Influenza Vaccination and Correlates of the Use of Enhanced Vaccines among Italian Adults. Vaccines 11:12, pages 1748.
Crossref
Allison L Naleway, Sara S Kim, Brendan Flannery, Min Z Levine, Kempapura Murthy, Suryaprakash Sambhara, Shivaprakash Gangappa, Laura J Edwards, Sarah Ball, Lauren Grant, Tnelda Zunie, Weiping Cao, F Liaini Gross, Holly Groom, Alicia M Fry, Danielle Hunt, Zuha Jeddy, Margarita Mishina, Meredith G Wesley, Sarah Spencer, Mark G Thompson, Manjusha Gaglani & Fatimah S Dawood. (2023) Immunogenicity of High-Dose Egg-Based, Recombinant, and Cell Culture–Based Influenza Vaccines Compared With Standard-Dose Egg-Based Influenza Vaccine Among Health Care Personnel Aged 18–65 Years in 2019–2020. Open Forum Infectious Diseases 10:6.
Crossref
Harold J. Manley, Eduardo K. LacsonJrJr, Gideon Aweh, Nien Chen Li, Daniel E. Weiner, Dana C. Miskulin, Caroline M. Hsu, Toros Kapoian, Mary S. Hayney, Klemens B. Meyer & Doug S. Johnson. (2022) Seroresponse to Inactivated and Recombinant Influenza Vaccines Among Maintenance Hemodialysis Patients. American Journal of Kidney Diseases 80:3, pages 309-318.
Crossref
Alexander Domnich & Chiara de Waure. (2022) Comparative effectiveness of adjuvanted versus high-dose seasonal influenza vaccines for older adults: a systematic review and meta-analysis. International Journal of Infectious Diseases 122, pages 855-863.
Crossref
Dawid Pieper, Irma Hellbrecht, Linlu Zhao, Clemens Baur, Georgia Pick, Sarah Schneider, Thomas Harder, Kelsey Young, Andrea C. Tricco, Ella Westhaver & Matthew Tunis. (2022) Impact of industry sponsorship on the quality of systematic reviews of vaccines: a cross-sectional analysis of studies published from 2016 to 2019. Systematic Reviews 11:1.
Crossref
Gaëtan Gavazzi, Anne Mosnier, Pascal Crepey & Jacques Gaillat. (2022) Vaccin grippal haute dose : un vaccin adapté aux 65 ans et plus. La Presse Médicale Formation 3:2, pages 105-118.
Crossref
Liang Chen, Xiudi Han, YanLi Li, Chunxiao Zhang & Xiqian Xing. (2021) The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia. Annals of Clinical Microbiology and Antimicrobials 20:1.
Crossref
Lars Pelz, Daniel Rüdiger, Tanya Dogra, Fadi G. Alnaji, Yvonne Genzel, Christopher B. Brooke, Sascha Y. Kupke & Udo Reichl. (2021) Semi-continuous Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing the Dynamic Competition To Select Candidates for Antiviral Therapy. Journal of Virology 95:24.
Crossref
Jayne Doherty, Sean Fennessy, Roisin Stack, Neil O’ Morain, Garret Cullen, Elizabeth J. Ryan, Cillian De Gascun & Glen A. Doherty. (2021) Review Article: vaccination for patients with inflammatory bowel disease during the COVID‐19 pandemic. Alimentary Pharmacology & Therapeutics 54:9, pages 1110-1123.
Crossref
Anja Kwetkat, Hans Jürgen Heppner, Anne-Sophie Endres & Andreas H. Leischker. (2021) Aktuelles zur Grippeimpfung und COVID-19-Auffrischimpfung. Geriatrie-Report 16:4, pages 10-15.
Crossref
Ogie Q. Umasabor-Bubu, Omonigho M. Bubu, Alfred K. Mbah, Mohamed Nakeshbandi & Tonya N. Taylor. (2021) Association between Influenza Vaccination and severe COVID-19 outcomes at a designated COVID-only hospital in Brooklyn. American Journal of Infection Control 49:10, pages 1327-1330.
Crossref
Anja Kwetkat, Hans Jürgen Heppner, Anne-Sophie Endres & Andreas Leischker. (2021) InfluenzaInfluenza. Der Internist 62:8, pages 801-806.
Crossref
Lee-Jah Chang, Evan J. Anderson, Robert Jeanfreau, Ying He, Bryony Hicks, Anju Shrestha, Aseem Pandey, Victoria Landolfi & Iris DeBruijn. (2021) Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial. Vaccine 39:11, pages 1572-1582.
Crossref
Florian Colrat, Edward Thommes, Nathalie Largeron & Fabián P. Alvarez. (2021) Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review. Vaccine 39, pages A42-A50.
Crossref
Freddy Caldera, Monica Mercer, Sandrine I. Samson, Jonathan M. Pitt & Mary S. Hayney. (2021) Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity. Vaccine 39, pages A15-A23.
Crossref
Alejandro E. Macias, Janet E. McElhaney, Sandra S. Chaves, Joshua Nealon, Marta C. Nunes, Sandrine I. Samson, Bruce T. Seet, Thomas Weinke & Hongjie Yu. (2021) The disease burden of influenza beyond respiratory illness. Vaccine 39, pages A6-A14.
Crossref
Janet E. McElhaney, Chris P. Verschoor, Melissa K. Andrew, Laura Haynes, George A. Kuchel & Graham Pawelec. (2020) The immune response to influenza in older humans: beyond immune senescence. Immunity & Ageing 17:1.
Crossref
Alexander Domnich, Maura Cambiaggi, Alessandro Vasco, Luca Maraniello, Filippo Ansaldi, Vincenzo Baldo, Paolo Bonanni, Giovanna Elisa Calabrò, Claudio Costantino, Chiara de Waure, Giovanni Gabutti, Vincenzo Restivo, Caterina Rizzo, Francesco Vitale & Riccardo Grassi. (2020) Attitudes and Beliefs on Influenza Vaccination during the COVID-19 Pandemic: Results from a Representative Italian Survey. Vaccines 8:4, pages 711.
Crossref
John P. Moore & P. J. Klasse. (2020) COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds. Journal of Virology 94:17.
Crossref
J. Bradley Layton, Leah J. McGrath, John M. Sahrmann, Yinjiao Ma, Vikas R. Dharnidharka, Caroline O'Neil, David J. Weber & Anne M. Butler. (2020) Comparative safety of high-dose versus standard-dose influenza vaccination in patients with end-stage renal disease. Vaccine 38:33, pages 5178-5186.
Crossref
Elena V. Vassilieva, Dahnide W. Taylor & Richard W. Compans. (2019) Combination of STING Pathway Agonist With Saponin Is an Effective Adjuvant in Immunosenescent Mice. Frontiers in Immunology 10.
Crossref
Robert L Atmar & Wendy A Keitel. (2019) Searching for Improved Flu Vaccines—The Time Is Now. The Journal of Infectious Diseases.
Crossref
Lee-Jah Chang, Ya Meng, Helene Janosczyk, Victoria Landolfi & H. Keipp Talbot. (2019) Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial. Vaccine 37:39, pages 5825-5834.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.